Prospect: information for the patient
Tuscalman 3 mg/ml Syrup
Noscapine hydrochloride
Read this prospect carefully before starting to take this medicine, as it contains important information for you.
Contents of the package and additional information
Noscapine is a central antitussive agent that acts by temporarily reducing the urge to cough.
Tuscalman is indicated for the symptomatic treatment of all forms of non-productive cough (dry cough).
Warnings and precautions
Consult your doctor or pharmacist before starting to take Tuscalman. This medication may cause drowsiness.
It may potentiate the effects of alcohol, so it is advisable to avoid the consumption of alcoholic beverages during treatment.
Inform your doctor of your current and past medical problems, especially diabetes and any allergy you may suffer.
Taking Tuscalman with other medications
Inform your doctor or pharmacist if you are using, have used recently or may have to use any other medication.
The concomitant use of Tuscalman and sedative medications such as benzodiazepines or related medications increases the risk of drowsiness, difficulty breathing (respiratory depression), coma, and may be potentially fatal. Therefore, concomitant use should only be considered when other treatment options are not possible.
However, if your doctor prescribes Tuscalman along with sedative medications, your doctor should limit the dose and duration of concomitant treatment.
Inform your doctor about all sedative medications you are taking and follow your doctor's recommendations carefully regarding the dose. It may be helpful to inform friends or family members who are aware of the signs and symptoms mentioned above. Contact your doctor when you experience these symptoms.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or if you think you may be pregnant or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Since there are not enough data to confirm its safety, as a precaution, it is not recommended to take it during pregnancy.
There are no data on the passage of Tuscalman to breast milk, so it is not recommended to use it during breastfeeding.
Driving and operating machinery
Since taking this medication may affect your reaction time, it is recommended to pay special attention if you drive vehicles or operate hazardous machinery, and do not exceed the recommended daily dose prescribed by your doctor.
Tuscalman contains saccharose, sorbitol, and sodium benzoate
This medication contains saccharose. If your doctor has indicated that you suffer from an intolerance to certain sugars, consult with him before taking this medication.
Patients with diabetes mellitus should note that this medication contains 5.130 g of saccharose per 10 ml.
This medication contains 87.15 mg of sorbitol in each ml.
Sorbitol is a source of fructose. If your doctor has indicated that you (or your child) suffer from an intolerance to certain sugars, or have been diagnosed with hereditary fructose intolerance (HFI), a rare genetic disease, in which the patient cannot break down fructose, consult with your doctor (or your child) before taking this medication.
This medication contains 1 mg of sodium benzoate per ml.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Remember to take your medication.
Your doctor will indicate the duration of treatment with Tuscalman.
Do not discontinue treatment as symptoms will reappear.
This medication and its administration method have been prescribed exclusively for you. Do not give it to other people or use it for other types of disorders.
Tuscalman should be taken preferably after meals.
The recommended dose is:
AdultsThe recommended dose is 2 dessert spoons (2 x 5 ml) every 5-6 hours.
Use in children and adolescents:
Children 2 to 6 years old: Half a dessert spoon (2.5 ml) every 5-6 hours.
Children 6 to 12 years old: 1 dessert spoon (5 ml) every 5-6 hours.
If you take more Tuscalman than you should
The most frequent symptom in case of overdose is excessive drowsiness.
Overdose treatment consists of inducing vomiting through the administration of emetics or gastric lavage.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forgot to take Tuscalman
Do not take a double dose to compensate for the missed doses. Limit yourself to taking the next dose as usual.
The most frequent adverse effects are: drowsiness, headache, nausea, and allergic reactions such as nasal mucosa inflammation, eye redness, skin rash, and skin itching.
These effects are generally mild and usually do not present significant importance.
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is about possible adverse effects that do not appear in this prospectus. You can also report them directly through theSpanish System for Pharmacovigilance of Medicinal Products for Human Use:www.notificaRAM.es.By reporting adverse effects, you can contribute to providing more information about the safety of this medication.
Keep this medication out of the sight and reach of children.
Store in the original packaging to protect it from light.
Once the container is opened, it expires after 6 months.
Do not use this medication after the expiration date that appears on the container after CAD. The expiration date is the last day of the month indicated.
Medications should not be disposed of through drains or trash. Dispose of containers and unused medications at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of containers and unused medications. By doing so, you will help protect the environment.
Appearance of the product and content of the packaging
Tuscalman is presented in the form of a dark yellow solution.
Each package contains 150 ml.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
Laboratorio Farmaceutico SIT, S.r.l.
Via Cavour 70
27035 Mede (Pavia)
Italy
Responsible for manufacturing
Laboratorio Farmaceutico S.I.T. Specialità Igienico Terapeutichi S.r.l
Via Provinciale per Lecco, 78.
22038 Tavernerio (Como)
Italy
You can request more information about this medication by contacting the local representative of the holder of the marketing authorization:
DESMA Laboratorio Farmacéutico SL
Paseo de la Castellana 121, escalera Izquierda 3ºB
28046 Madrid, Spain
Last review of this prospect was in: May 2024
Other sources of information
The detailed and updated information about this medication is available on the
website of the Spanish Agency for Medicines and Medical Devices (AEMPS)
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.